The report "PARP Inhibitors in Oncology" combines key opinion leader insight with in-house analyst expertise and research to provide an insight-rich look at PARP inhibitors in the US, Europe, and Asia. PARP inhibitors continue to lead progress in ovarian cancer. What are the challenges coming in the way of application in other oncology areas? Get the full picture!